QuantLogix ← JNJ scorecard
📅 JNJ Earnings Preview
Johnson & Johnson
Next report (est.)
September 5, 2026
Countdown
84 days
EPS growth YoY
-52.9%
Revenue growth YoY
+9.9%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
April 22, 2026 ±2.3% -0.0% over-priced
October 22, 2025 ±1.4% +0.6% over-priced
July 24, 2025 ±1.5% +0.3% over-priced
April 23, 2025 ±2.3% -1.5% over-priced
October 23, 2024 ±1.2% +1.5% under-priced
July 25, 2024 ±1.7% +2.1% under-priced
May 1, 2024 ±1.5% +4.6% under-priced
October 27, 2023 ±1.4% -2.3% under-priced
Across these reports, options implied an average ±1.7% move vs an actual average of 1.6% — the stock stayed inside the implied band 50% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q4 FY2026 $2.14 $24.1B $5.2B
Q4 FY2025 $2.09 $24.6B $5.1B
Q3 FY2025 $2.12 $24.0B $5.2B
Q2 FY2025 $2.29 $23.7B $5.5B
Analyst posture
Buy / Strong Buy
21
Hold
10
Sell
0
Stable: +2 net change 30d
Live 5-factor engine read: Buy · 63/100 Full scorecard →
Get alerted before every JNJ report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on JNJ before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Johnson & Johnson (JNJ) reports in 84 days, with the next report estimated for September 5, 2026. Across the last 8 reports, options priced an average ±1.7% earnings move while the stock actually moved 1.6% on average — the market has been roughly fair on JNJ's earnings risk. Fundamentals into the print: EPS down 52.9% year-over-year, revenue up 9.9%. QuantLogix's live 5-factor engine currently reads JNJ as a buy at 63/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →